Adjusted analysis revealed no difference in time to first CV event if MRA was added/intensified in those with elevated galectin-3 ( hazard ratio 0.99 , 95 % CI 0.97-1 .02 , P = .74 ) ; similarly , cumulative MRA dose was not a specific predictor of benefit .